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Introduction
Painful bladder syndrome is characterized by suprapubic pain related to bladder filling, coupled with additional symptoms, such as increased daytime and nighttime urinary frequency, without proven urinary infection or other obvious pathology [1] . The disease is chronic and highly debilitating and has a great negative impact on the quality of life of patients. Several causes have been postulated in the pathogenesis of the condition, including infection, autoimmune response, allergic reaction, neurogenic inflammation, epithelial dysfunction, and inherited susceptibility, but the etiology remains unknown [2] . A number of pharmacologic treatments have been used to treat the pathology; currently, among new potentially effective treatment modalities, botulinum A toxin (BTX-A) intravesical treatment is under investigation.
BTX-A intravesical injections have been demonstrated to be an effective treatment for both neurogenic and nonneurogenic detrusor overactivity [3, 4] , without producing any consistent axonal sprouting within the detrusor muscle [5] .
Recent experimental and clinical evidence suggests also an effect of BTX-A on afferent C fibers, which should explain the antinociceptive effect on bladder tissue in rat chemical cystitis models [6] and in patients with interstitial cystitis [7] .
Recently, the ability of a catalytically active derivative of BTX-A to block the secretion from vesicle populations in dorsal root ganglia neuronal cultures has been demonstrated for the release of substance P and glutamate, which are involved in afferent nociceptive transmission to the central nervous system [8] . This evidence supports the clinical application of BTX-A in the treatment of bladder hypersensitive disorders in humans.
The aim of the present study was to evaluate the efficacy and tolerability of BTX-A intravesical treatment in patients with painful bladder symptoms associated with increased urinary frequency that was refractory to conventional treatment modalities.
2.
Materials and methods
Patients
The patients enrolled in this prospective study were affected by refractory bladder pain and urgency frequency syndrome, in the presence of sterile urine. The study was approved by the local ethics committee and all patients gave their written informed consent. Patients with myasthenia gravis and other diseases affecting cholinergic action, pregnancy, and concomitant use of aminoglycosides were excluded from the study. Furthermore, we excluded patients with concomitant bladder outlet obstruction, prior radiotherapy, and intravesical stones. Previous treatment modalities, including oral and intravesical therapies, have failed in all patients. Particularly, failing treatments consisted of anticholinergics per os, antidepressants, bladder overdistention, pentosan polysulfate per os, and resiniferatoxin intravesical passive diffusion. In addition, one patient was treated previously with sacral nerve modulation ( Table 1 ). All patients presented with increased daytime and nighttime urinary frequency (Table 2) and pain in the bladder and urethra, vagina, or perineum during bladder filling or after micturition. Two men, who previously had transurethral resection of bladder tumors and then were treated with intravesical bacillus Calmette-Gué rin, complained of severe bladder and perineal pain with urgency-frequency syndrome.
Baseline evaluation included history, physical examination, serum chemistries, urinalyses, urine culture, and imaging assessment of the upper and lower urinary tract. Patients underwent voiding chart, cystoscopy, and urodynamics and used the Visual Analog Scale (VAS) for pain quantification. Urodynamics followed the International Continence Society Standards [9] , and it was performed 1 mo before commencing the study.
Study plan and treatment
Fourteen patients fulfilling all criteria were selected and included in the study. Under short general anesthesia patients were given injections of 200 U of commercially available BTX-A (Allergan, Irvine, CA) diluted in 20 ml 0.9% NaCl. Injections were performed through a cystoscope using a flexible needle, submucosally in the trigone and bladder floor. A total of 10 U BTX-A was used per injection site. After BTX-A injections, a 16 Ch Foley indwelling catheter was routinely inserted for 24 h. Patients were discharged after overnight observation and were followed up for bladder voiding and pain. Uroflowmetry with postvoid residual volume measurements was performed after the catheter was removed. Clinical evaluation, VAS score, cystoscopy, and urodynamics were repeated after 1 and 3 mo. Local or systemic side effects were noted during and after treatment.
Data analysis
Statistical analysis was performed using the Friedman, Wilcoxon, and Mann-Whitney tests for nonparametric data. The Bonferroni correction was applied to post hoc multiple comparisons. Statistical significance was set at p < 0.05. All data analyses were performed using SPSS release 10.1.1 for Windows (SPSS Inc., Chicago, IL, 1999).
Results
The 12 women and 2 men had a mean age of 64 AE 9.6 yr and mean disease duration of 3.7 AE 2.2 yr. Before treatment, mean daytime and nighttime urinary frequencies were 14.2 AE 3.8 and 4.5 AE 1.3, respectively, and the mean VAS score was 9.3 AE 0.9. On urodynamics, all patients demonstrated abnormal sensation (first desire <150 ml) in the absence of detrusor overactivity. Mean cystometric capacity was 261.6 AE 34.8 ml; no patient had impaired detrusor contractility. Twenty-four hours after BTX-A treatment, 2 patients (1 man and 1 woman) needed complementary intermittent catheterization, due to large postvoid residual volume.
One month after therapy, mean daytime and nighttime urinary frequencies were significantly reduced (8.4 AE 1.9 and 2.1 AE 1.5; p < 0.01 and p < 0.05, respectively). Twelve patients (85.7%) reported a subjective improvement in painful bladder symptoms; globally, the mean VAS score was 5.8 AE 2.4 ( p < 0.01). Ten patients complained of different grades of dysuria and needed abdominal straining to completely void their bladder. Furthermore, statistically significant improvements in urodynamic parameters were registered. The mean value of maximum cystometric capacity increased from 261.6 AE 34.8 to 359.7 AE 48.4 ml ( p < 0.01). Globally, we could detect a significant reduction in detrusor pressure at maximum flow rate and in e u r o p e a n u r o l o g y 4 9 ( 2 0 0 6 ) 7 0 4 -7 0 9 706 Table 2 . Three months after treatment, the mean VAS score was 6.1 AE 2.8 ( p < 0.01); 12 patients reported again a consistent improvement in their symptoms, but in 4 patients dysuria persisted. Two patients persisted with complementary intermittent self-catheterization. Mean daytime and nighttime urinary frequencies were 9.1 AE 2.3 and 2.4 AE 1.7, respectively ( p < 0.01 and p < 0.05). Maximum cystometric capacity was substantially similar to that detected at 1 mo follow-up. We did not observe any systemic side effects during or after treatment. All patients were interviewed by telephone at 5 mo follow-up. Bladder pain had recurred in 10 patients and the mean VAS score was 8.6 AE 0.2. Two patients complained of dysuria and one was still using intermittent self-catheterization.
Discussion
Apart from its therapeutic effects to block both striated and smooth muscle contractions, increasing evidence has shown that BTX-A also has analgesic properties in animals and humans. A peripheral antinociceptive effect of the neurotoxin has been suspected on the basis of the reduction in pain associated with migraine headaches, spasmodic torticollis, and chronic myofascial pain [10] [11] [12] . Welch et al. observed that various botulinum toxins inhibited release of neuropeptides from rat dorsal root ganglia [13] , and Jabbari et al. reported that multiple subcutaneous BTX-A injections relieved segmental burning pain [14] . Few studies revealed the benefits of BTX-A injections in patients suffering from the urgencyfrequency syndrome or interstitial cystitis. Zermann et al. showed reduced frequency and increased bladder capacity in 4 of 7 patients with refractory urgency-frequency syndrome who received intravesical Botox targeting the trigone and bladder base [15] . A recent multicenter case series examined the effect of intravesical Botox or Dysport in 13 patients with refractory interstitial cystitis [16] . Overall, 9 of 13 patients (69%) reported a subjective improvement that lasted a mean of 3.72 mo (range, 1-8 mo).
The present study shows that intravesical BTX-A injection successfully relieved pain for a few months in most patients with painful bladder syndrome. Exactly how BTX-A works in the bladder is as yet unclear. Cholinergic blockade at the neuromuscular junction does not account for such sensory effects. Maggi et al. showed that bladder sensory nerves have dual afferent and efferent nerve functions [17] . The sensory efferent actions include the release of transmitters such as adenosine triphosphate (ATP), substance P, and calcitonin gene-related peptide (CGRP) that can act on nearby tissues and on afferent nerve terminals in an autocrine fashion to increase afferent nerve activity [17] . The production and release of these neurotransmitters increase during conditions of inflammation and pain [7, 16] . Moreover, many C fibers in the bladder mucosa contain neuropeptides, such as substance P, neurokinin A, and CGRP, which on release, can modulate the micturition reflex and might cause detrusor overactivity [18] .
Another neurotransmitter involved in inflammation is ATP. Recently, it has been observed that BTX-A inhibits ATP release from bladder urothelium in rats [18] , and increased stretch activated ATP release has been reported from human urothelial cells cultured from the bladders of patients with interstitial cystitis and spinal cord injury [19] .
Finally, it has been observed that BTX-A intravesical injections reduce nerve growth factor (NGF) bladder tissue content in patients with spinal cord injury (SCI) patients with detrusor overactivity [20] . NGF, which is increased not only after SCI, but also in inflamed tissues and in serum of patients with inflammatory conditions, has been shown to act on trkA receptors to mediate substance P biosynthesis and release from afferent neurons [21] . Once released from afferent terminals, substance P acts on NK1 receptors and mediates neurogenic inflammation consisting of increased vascular permeability, plasma extravasation, glandular secretion, and proinflammatory cell influx.
Indeed, the mechanisms underlying the antinociceptive effect of BTX-A may be more complex because recent observations revealed that human urothelium also receives cholinergic innervation and can release acetylcholine at rest [22] . This nonneural acetylcholine could bind to muscarinic receptor populations within urothelium or afferent nerves, thereby modulating bladder sensory input to the central nervous system.
In the present study, the significant increase in bladder capacity and the reduction in urinary frequency, as observed at 1 and 3 mo follow-up, can be explained by the ability of BTX-A to spread into close tissues. Thus, at least the lateral walls of the bladder could have been influenced by the action of the neurotoxin. Indeed, the decrease in sensory input from the bladder to the central nervous system could e u r o p e a n u r o l o g y 4 9 ( 2 0 0 6 ) 7 0 4 -7 0 9 explain the reduction in frequency. Moreover, the relief of pain itself may have been an adjunctive factor supporting frequency amelioration.
One major concern in the present study was that BTX-A impaired detrusor contractility in 6 of 14 patients, even though it was administered submucosally. Indeed, incomplete bladder emptying represents a serious complication in nonneurogenic patients who are not used to performing selfcatheterization. BTX-A may have spread into underlying tissues, thus reaching muscarinic receptors in the detrusor muscle. In future studies this complication should be avoided by reducing the dosage or dilution or by using intravesical instillation, which can be administered without general anesthesia. However, because the molecular weight of BTX-A is 150 kD, penetrating the intact urothelium is difficult and mucosal permeability may need to be increased before administering BTX-A. This approach would prevent BTX-A from reaching the muscle layer and limit its action to the bladder mucosa, thus relieving bladder pain without modifying detrusor contractility.
One final point is worth mentioning. Because the effects of BTX-A toxin are transient, repeated doses, as indeed our patients requested, are needed for effective control of bladder pain and urgency. The dose with the longest duration and lowest risk of urinary retention still needs to be established.
Conclusions
The results of this pilot study indicate that BTX-A intravesical injections are effective in the shortterm management of painful bladder syndrome. By modulating afferent C-fiber activity within the bladder walls, BTX-A significantly improves urodynamic parameters and reduces bladder pain and urinary frequency. The injection of the neurotoxin into the bladder wall impairs detrusor contractility in a minority of patients. No systemic side effects were observed during and after treatment. Further research is needed to explore the underlying mechanisms (eg, neuronal, afferent, or efferent) of analgesia induced by BTX-A.
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Chronic pelvic pain syndrome (CPPS) is an entity of unknown origin that affects a large number of both men ad women. The impact of CPPS on the patients quality of life is immense, with a negative impact on social activities, personal relationships, sexuality and physical activityas well as psychological well being [1] .
Following clinical suspicion of CPPS the diagnosis is not as in most diseases confirmed by a positive findings on objective examinations, but rather by an extensive diagnostic work up excluding other urological abnormalities. This because the true pathology behind this symptom complex remains an enigma [2] . Many authors believe in an inflammatory process, however to date a pathogen has not been found. Another potential mechanism is a neuroinflammatory cascade evoking an increased pain response.
The same problem arises when it comes to treating the patient. There are multiple therapeutic options ranging from antibiotic treatment to cystectomy and bladder substitution.
Here a pilot study is presented using botulinum A toxin injections into the trigone and bladder floor for the treatment of CPPS. Eighty-six percent of patients reported a subjective improvement at 1 and 3 months. This further increases the evidence, that Botulinum A toxin has an antinociceptive effect [3] . If this is through an effect on afferent pathways, efferent pathways or urothelial cell activity remains to be determined. Another interesting point is the role of the trigone in CPPS, which remains unclear and published results are controvers [3, 4] .
Overall the use of botulinum A toxin for treating CPPS is a promising minimally invasive concept. In future better understanding of the pathogenetic mechanism behind CPPS may help us choose the most appropriate treatment option for each individual patient.
